Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Can a High Reloading Dose of Atorvastatin Prior to Percutaneous Coronary Intervention Reduce Periprocedural Myocardial Infarction?
Abstract Background : Periprocedural myocardial infa rct ion ( MI ) is a common complication following percutaneous coronary intervention ( PCI ) and statins have been shown to reduce MI in statin-naïve patients . We aim ed to identify whether a high reloading dose of atorvastatin can prevent MI following PCI in patients who were already being treated with statins . Material and methods : In this triple-blind controlled r and omized clinical trial , 190 c and i date s for elective PCI , who were already using statins and /or other lipid lowering agents such as fibrates  , were r and omly assigned to two equal groups to receive either atorvastatin ( 80 mg ) or placebo within 24 hours before the procedure . Serum levels of creatinine kinase myocardial isoenzyme ( CK-MB ) , cardiac troponin I ( cTNI ) and high-sensitive C-reactive protein ( hs-CRP ) were measured at baseline and then 6 and 12 hours following PCI . Post-procedural MI was defined as troponin elevation > 5-fold in patients with normal baseline or > 20 % in those with elevated baseline measurements with or without chest pain or ST segment or T wave abnormalities . Results : Frequency of MI in the atorvastatin group was 3 ( 3.1 % ) vs. 10 ( 10.5 % ) in the placebo group ( p = 0.04 ) . The CK-MB rise within 6 hours following PCI was 0.6 ± 0.3 mg/dl in the intervention group versus 3.0 ± 1.6 mg/dl in the placebo group . Also , the levels of cTNI within 6 and 12 hours in the intervention group was significantly lower than the placebo group ( p = 0.01 and 0.008 , respectively ) . hs-CRP was significantly lower in the intervention group after 12 hours ( p = 0.004 ) . Conclusion : Administration of a high reloading dose of atorvastatin within 24 hours before PCI could significantly reduce the frequency of periprocedural MI . Clinical trial registration code : I RCT 201205209768N1
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .